Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.

M, Roffi; D, Mukherjee; DP, Chew; DL, Bhatt; L, Cho; MA, Robbins; KM, Ziada; DM, Brennan; SG, Ellis; EJ, Topol

doi:10.1161/01.cir.0000041250.89627.a9

Public

Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.

Shared by NobleBlocks on Dec 1, 2002 • 12:00 AM UTC

Authors:

Roffi M

Mukherjee D

Chew DP

Abstract

Background Despite widespread use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors for percutaneous coronary interventions (PCI) of bypass grafts, data supporting this strategy are lacking.Methods and results A pooled analysis of 5 randomized intravenous GP IIb/IIIa inhibitor trials (EPIC,...

Discussions